首页> 外文期刊>Molecular cancer therapeutics >Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
【24h】

Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.

机译:介导新型激酶抑制剂细胞毒性的非激酶靶标的鉴定。

获取原文
获取原文并翻译 | 示例
           

摘要

In developing inhibitors of the LIM kinases, the initial lead molecules combined potent target inhibition with potent cytotoxic activity. However, as subsequent compounds were evaluated, the cytotoxic activity separated from inhibition of LIM kinases. A rapid determination of the cytotoxic mechanism and its molecular target was enabled by integrating data from two robust core technologies. High-content assays and gene expression profiling both indicated an effect on microtubule stability. Although the cytotoxic compounds are still kinase inhibitors, and their structures did not predict tubulin as an obvious target, these results provided the impetus to test their effects on microtubule polymerization directly. Unexpectedly, we confirmed tubulin itself as a molecular target of the cytotoxic kinase inhibitor compounds. This general approach to mechanism of action questions could be extended to larger data sets of quantified phenotypic and gene expression data.
机译:在开发LIM激酶抑制剂时,最初的先导分子将有效的靶标抑制作用与有效的细胞毒活性结合在一起。然而,当评估随后的化合物时,细胞毒性活性与对LIM激酶的抑制作用分离。通过整合两种可靠的核心技术的数据,可以快速确定细胞毒性机制及其分子靶标。高含量测定和基因表达谱均表明对微管稳定性有影响。尽管细胞毒性化合物仍是激酶抑制剂,并且它们的结构并未预测微管蛋白是明显的靶标,但这些结果为直接测试其对微管聚合的作用提供了动力。出乎意料的是,我们证实微管蛋白本身是细胞毒性激酶抑制剂化合物的分子靶标。这种作用机制问题的一般方法可以扩展到更大的量化表型和基因表达数据集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号